Drugs Made In America Acquisition Corp.
DMAAFinancial ServicesNASDAQShell Companies · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the financial services sector, Drugs Made In America Acquisition Corp. (DMAA) is listed under Shell Companies. The $261.9M market capitalization puts DMAA squarely in micro-cap range for its industry. does not have significant operations.
Market Cap
$261.9M
Beta
—
P/E (TTM)
59.94
P/E (Fwd)
—
EPS (TTM)
$0.18
EPS (Fwd)
—
ROE
—
ROA
—
Cash
$20,280
Total Debt
$350,000
Free CF
—
52W Change
4.7%
Annual Financials
Cash vs Debt
Where DMAA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DMAA finished 1.70% above its 150-day moving average ($10.58) and 2.18% above its 200-day moving average ($10.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMAA overbought or oversold?
At the September 3, 2026 close, DMAA's RSI(14) was 77.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, DMAA has $20K in cash with $350K in obligations. The ability to service this debt comfortably depends on continued operational cash generation.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing DMAA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.